Nucleases in gene-editing technologies: past and prologue

被引:0
|
作者
Dan-Yuan Li [1 ,2 ]
Long-Qi Li [1 ,2 ]
Jun-Jie Gogo Liu [1 ,2 ]
机构
[1] Beijing Advanced Innovation Center for Structural Biology, Frontier Research Center for Biological Structure, School of Life Sciences,Tsinghua University
[2] Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University
基金
中国国家自然科学基金;
关键词
D O I
暂无
中图分类号
Q78 [基因工程(遗传工程)];
学科分类号
071007 ; 0836 ; 090102 ;
摘要
In recent decades, gene-editing technologies, typically based on deoxyribonucleases to specifically modify genomic sequences, have dramatically remodeled various aspects of life sciences, including fundamental research, breeding, and medical therapeutics. So far, four types of endonucleases have been adopted and optimized as gene-editing tools: meganuclease, ZFN, TALEN, and Cas nuclease from the CRISPR-Cas system. Each tool comes with its own advantages and limitations. Over the last ten years, RNA-guided Cas nucleases have been extensively investigated and successfully implemented in almost all mammalian cells due to their remarkable editing efficacy, high specificity, and flexibility in targeting the specific locus. Diverse Cas nuclease, together with meganuclease, ZFN, and TALEN, represent the key strategies for nuclease-based gene editing. However, systematic introductions and comparisons among four types of nucleases are not yet available. Here, we overview the capabilities of four types of nucleases along the development history of gene editing and describe the molecular mechanisms of substrate recognition and cleavage. Particularly, we summarize the promising CRISPR-Cas systems as well as modified tools applied for gene editing in the eukaryotic genome. Moreover, how the re-modulated nucleases and other nucleases, either naturally occurring or AI-designed, might manipulate DNA sequences is discussed and proposed.
引用
收藏
页码:25 / 56
页数:32
相关论文
共 50 条
  • [41] Novartis expands gene-editing program
    Cross, Ryan
    [J]. CHEMICAL & ENGINEERING NEWS, 2017, 95 (46) : 13 - 13
  • [42] AN ETHICALLY FRAUGHT GENE-EDITING CLAIM
    Enserink, Martin
    [J]. SCIENCE, 2018, 362 (6421) : 1353 - 1353
  • [43] Gene-editing pipeline takes off
    Asher Mullard
    [J]. Nature Reviews Drug Discovery, 2020, 19 : 367 - 372
  • [44] The gene-editing of super-ego
    Hofmann, Bjorn
    [J]. MEDICINE HEALTH CARE AND PHILOSOPHY, 2018, 21 (03) : 295 - 302
  • [45] House drops gene-editing ban
    Brainard, Jeffrey
    [J]. SCIENCE, 2019, 364 (6443) : 810 - 810
  • [46] Call for human gene-editing rules
    不详
    [J]. NEW SCIENTIST, 2019, 241 (3212) : 6 - 6
  • [47] China is not winning the gene-editing race
    Le Page, Michael
    [J]. NEW SCIENTIST, 2018, 237 (3163) : 25 - 25
  • [48] Emerging Gene-Editing Modalities for Osteoarthritis
    Tanikella, Alekya S.
    Hardy, Makenna J.
    Frahs, Stephanie M.
    Cormier, Aidan G.
    Gibbons, Kalin D.
    Fitzpatrick, Clare K.
    Oxford, Julia Thom
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (17) : 1 - 14
  • [49] CRISPR snapshots of a gene-editing tool
    Petya V Krasteva
    [J]. Nature Methods, 2014, 11 : 365 - 365
  • [50] Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools
    Hasanzadeh, Akbar
    Ebadati, Arefeh
    Dastanpour, Lida
    Aref, Amir R.
    Zangabad, Parham Sahandi
    Kalbasi, Alireza
    Dai, Xiaofeng
    Mehta, Geeta
    Ghasemi, Amir
    Fatahi, Yousef
    Joshi, Suhasini
    Hamblin, Michael R.
    Karimi, Mahdi
    [J]. ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2023, 6 (12) : 1758 - 1779